US 12,391,653 B2
Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor
Yaxian Cai, Shanghai (CN); Bao Yue, Shanghai (CN); Peng Yu, Shanghai (CN); Changqing Wei, Shanghai (CN); and Wenyuan Qian, Shanghai (CN)
Assigned to KPC PHARMACEUTICALS, INC, Yunnan (CN)
Appl. No. 17/787,680
Filed by KPC PHARMACEUTICALS, INC, Yunnan (CN)
PCT Filed Dec. 22, 2020, PCT No. PCT/CN2020/138174
§ 371(c)(1), (2) Date Jun. 21, 2022,
PCT Pub. No. WO2021/129587, PCT Pub. Date Jul. 1, 2021.
Claims priority of application No. 201911335601.7 (CN), filed on Dec. 23, 2019.
Prior Publication US 2023/0045991 A1, Feb. 16, 2023
Int. Cl. C07D 235/30 (2006.01)
CPC C07D 235/30 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystalline form A of compound represented by formula (I), wherein its X-ray powder diffraction spectrum shows characteristic diffraction peaks at 2θ angles of 9.78±0.20°, 12.06±0.20° and 20.37±0.20°;

OG Complex Work Unit Chemistry